WebJul 21, 2024 · SMARCA4 - deficient undifferentiated tumors were recently recognized as a new entity in the WHO classification of thoracic tumors and are defined as malignant neoplasms with an... WebApr 4, 2024 · Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor. SWI/SNF Complex-deficient Undifferentiated Carcinoma of the Gastrointestinal Tract: Clinicopathologic Study of 30 Cases With an Emphasis on Variable Morphology, Immune Features, and the Prognostic Significance of Different SMARCA4 and SMARCA2 …
SMARCA4-Deficient Undifferentiated Tumor of Lung Mass—A
WebNov 1, 2024 · SMARCA4 is a member of the SWI/SNF chromatin-remodeling complex, which is a tumor suppressor that regulates transcription and promotes cell differentiation. There … WebSMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a recently described entity with an aggressive c ... in this setting the expression of SOX2, CD34, and SALL4 proved useful. All tested cases displayed concomitant loss of SMARCA4 and SMARCA2 and most tumors expressed epithelial markers (Pan-keratin or EMA) (n=29/30), SOX2 (n=26/27), and CD34 ... greenhouse layout app
Lung neuroendocrine neoplasms: recent progress and persistent …
WebApr 7, 2024 · SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) occurs predominantly in young men with a history of smoking, and patients usually die within a few months (Liu et al., 2024). The prognosis for SMARCA4-DTS is poor, there was strong positive expression of CK7, AE1/3, CAM5.2 and SALL4, and partial positive expression of CD34 and SOX2. WebWe explored clinicopathological features and treatment strategies for thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT).Thoracic SMARCA4-UT is a new entity recently acknowledged in the 2024 edition of World Health Organization Classification of Thoracic Tumors, and doctors are relatively unfamiliar with its diagnosis, treatment, and … WebJun 21, 2024 · All lung biopsies and those from metastatic sites in patients with suspected advanced lung cancer and classified as NSCC-NOS as per WHO (2015) guidelines were subjected to BRG1 testing by immunohistochemistry. SMARCA4/BRG1 protein-deficient thoracic tumors were evaluated by an extended immunohistochemistry panel. flybe website